Suppr超能文献

具有相当抗利什曼原虫活性且巨噬细胞细胞毒性显著降低的米替福新类似物。

Miltefosine analogues with comparable antileishmanial activity and significantly reduced macrophage cytotoxicity.

作者信息

Alonso Lais, Lemes Laís Flávia Nunes, Magoulas George E, Costa Brenda de Lucena, Gomes Rodrigo Saar, Dorta Miriam Leandro, Bolognesi Maria Laura, Romeiro Luiz Antonio Soares, Calogeropoulou Theodora, Alonso Antonio

机构信息

Universidade Federal de Goiás, Instituto de Física, Goiânia, GO, Brasil.

Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical, Laboratório de Desenvolvimento de Inovações Terapêuticas, Brasília, DF, Brasil.

出版信息

Mem Inst Oswaldo Cruz. 2025 May 26;120:e240219. doi: 10.1590/0074-02760240219. eCollection 2025.

Abstract

BACKGROUND

Miltefosine (MIL) is the only oral drug approved for leishmaniasis treatment, but its use is limited by gastrointestinal toxicity. Novel alkylphospholipid analogues may provide safer and more effective alternatives.

OBJECTIVES

This study aimed to assess the antileishmanial activity, cytotoxicity, and membrane interactions of three MIL analogues TC387, TC388, and TC437 against Leishmania amazonensis.

METHODS

Antileishmanial and cytotoxic activities were evaluated in L. amazonensis, J774.A1 macrophages, and erythrocytes. Membrane interactions were characterized using spin-label electron paramagnetic resonance (EPR) spectroscopy.

FINDINGS

TC387, TC388, and TC437 demonstrated EC50 values of 10-16 µM for intracellular amastigotes, compared to 17 µM for MIL, with selectivity indices (SI) ranging from 43-163, significantly higher than MIL's SI of 5. EPR data revealed that the analogues increased membrane protein dynamics and caused greater disruption at the lipid-protein interface of parasite membranes relative to MIL. This disruption likely enhances pore formation, ion leakage, and reactive oxygen species (ROS) production, leading to parasite death.

MAIN CONCLUSIONS

The MIL analogues TC387, TC388, and TC437 exhibited superior SI and comparable or slightly enhanced antileishmanial activity relative to MIL, along with very low hemolytic potential. These findings support further investigation of these analogues as promising oral therapeutic candidates for leishmaniasis.

摘要

背景

米替福新(MIL)是唯一被批准用于治疗利什曼病的口服药物,但其使用受到胃肠道毒性的限制。新型烷基磷脂类似物可能提供更安全、更有效的替代方案。

目的

本研究旨在评估三种米替福新类似物TC387、TC388和TC437对亚马逊利什曼原虫的抗利什曼活性、细胞毒性和膜相互作用。

方法

在亚马逊利什曼原虫、J774.A1巨噬细胞和红细胞中评估抗利什曼活性和细胞毒性。使用自旋标记电子顺磁共振(EPR)光谱对膜相互作用进行表征。

研究结果

与米替福新的17 μM相比,TC387、TC388和TC437对细胞内无鞭毛体的半数有效浓度(EC50)值为10-16 μM,选择性指数(SI)范围为43-163,显著高于米替福新的SI值5。EPR数据显示,与米替福新相比,这些类似物增加了膜蛋白动力学,并在寄生虫膜的脂-蛋白界面引起更大的破坏。这种破坏可能会增强孔形成、离子泄漏和活性氧(ROS)产生,从而导致寄生虫死亡。

主要结论

米替福新类似物TC387、TC388和TC437表现出优于米替福新的SI,抗利什曼活性相当或略有增强,且溶血潜力极低。这些发现支持进一步研究这些类似物作为利什曼病有前景的口服治疗候选药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验